We believe the most promising opportunities lie in solutions that are personalized, easy to use, and integrate seamlessly into patients' lives both during and after GLP-1 treatment
Transcription factor STAT3 as a novel molecular target for cancer prevention
"Unsustainable burden" Blue Cross Blue Shield said in 2024, five GLP-1 drug companies accounted for 20% of their total pharmacy spend which topped $300 million last year
This prolonged, supraphysiological stimulation results in greater glucose-lowering effects, more pronounced appetite suppression, and clinically significant weight loss that varies by medication and dose: approximately 5-8% with liraglutide 3 mg, 10-15% with semaglutide 2.4 mg, and 15-22% with tirzepatide at higher doses
They are introducing them early in their protocols
Injecting too fast forces a large bolus of liquid into a small subcutaneous space, which can cause pain, lump formation, and potentially altered absorption kinetics